Want to see HK:6833 full AI Analyst Report?
6833 Stock Chart & Stats
HK$0.18
HK$0.02(7.44%)
At close: 4:00 PM EST
HK$0.18
HK$0.02(7.44%)
Day’s Range― - ―
52-Week RangeHK$0.15 - HK$0.28
Previous CloseN/A
Volume2.13M
Average Volume (3M)210.00K
Market Cap
HK$325.26M
Enterprise ValueHK$103.33M
Total Cash (Recent Filing)HK$374.53M
Total Debt (Recent Filing)HK$183.47M
Price to Earnings (P/E)8.2
Beta0.27
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.12%
Share Statistics
EPS (TTM)0.02
Shares Outstanding2,032,890,600
10 Day Avg. Volume85,200
30 Day Avg. Volume210,000
Financial Highlights & Ratios
PEG Ratio-0.53
Price to Book (P/B)0.47
Price to Sales (P/S)0.16
P/FCF Ratio2.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving LeverageA materially lower debt-to-equity ratio enhances financial flexibility and reduces interest burden over the medium term. Improved leverage and rising equity support the firm's ability to fund operations, absorb shocks, and pursue strategic investments without heavy reliance on external debt.
Rebound In Operating And Free Cash FlowRestored positive OCF and FCF indicate the company can internally fund working capital and some investment, reducing financing dependence. If sustained, this improves resilience, supports dividend/capex capacity, and provides runway to execute strategic initiatives over coming quarters.
Consistent Positive Net IncomeMaintaining positive net income despite revenue pressure shows the business still generates earnings and can cover costs. This baseline profitability supports continuity of operations, helps retain stakeholders, and provides a platform for margin or revenue recovery over a multi-quarter horizon.
Bears Say
Sharp Revenue DeclineAn ~18% revenue drop materially reduces scale benefits and compresses operating leverage. Sustained top-line decline undermines ability to invest in growth, erodes bargaining power with suppliers/customers, and increases fixed-cost burden, making profitability recovery harder over months.
Structurally Thin MarginsLow and compressed margins leave limited room to absorb cost inflation or reinvest in the business. With operating and net margins near single digits, small adverse trends in revenue or costs can quickly push profits into loss, restricting long-term investment and shareholder return capacity.
Volatile Cash GenerationHistoric swings between positive and negative FCF signal execution and working-capital risk. Cash volatility complicates planning for capex, dividends, or debt repayment, and increases the chance of needing external financing in downturns, weakening durable financial stability.
Sinco Pharmaceuticals Holdings Ltd. News
6833 FAQ
What was Sinco Pharmaceuticals Holdings Ltd.’s price range in the past 12 months?
Sinco Pharmaceuticals Holdings Ltd. lowest stock price was HK$0.15 and its highest was HK$0.28 in the past 12 months.
What is Sinco Pharmaceuticals Holdings Ltd.’s market cap?
Sinco Pharmaceuticals Holdings Ltd.’s market cap is HK$325.26M.
When is Sinco Pharmaceuticals Holdings Ltd.’s upcoming earnings report date?
Sinco Pharmaceuticals Holdings Ltd.’s upcoming earnings report date is Sep 02, 2026 which is in 61 days.
How were Sinco Pharmaceuticals Holdings Ltd.’s earnings last quarter?
Sinco Pharmaceuticals Holdings Ltd. released its earnings results on Mar 26, 2026. The company reported HK$0.006 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.006.
Is Sinco Pharmaceuticals Holdings Ltd. overvalued?
According to Wall Street analysts Sinco Pharmaceuticals Holdings Ltd.’s price is currently Overvalued.
Does Sinco Pharmaceuticals Holdings Ltd. pay dividends?
Sinco Pharmaceuticals Holdings Ltd. pays a Annually dividend of HK$0.002 which represents an annual dividend yield of 1.12%. See more information on Sinco Pharmaceuticals Holdings Ltd. dividends here
What is Sinco Pharmaceuticals Holdings Ltd.’s EPS estimate?
Sinco Pharmaceuticals Holdings Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sinco Pharmaceuticals Holdings Ltd. have?
Sinco Pharmaceuticals Holdings Ltd. has 2,032,890,600 shares outstanding.
What happened to Sinco Pharmaceuticals Holdings Ltd.’s price movement after its last earnings report?
Sinco Pharmaceuticals Holdings Ltd. reported an EPS of HK$0.006 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.326%.
Which hedge fund is a major shareholder of Sinco Pharmaceuticals Holdings Ltd.?
Currently, no hedge funds are holding shares in HK:6833
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sinco Pharmaceuticals Holdings Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.16%
12-Months-Change
Fundamentals
Return on Equity
5.06%
Trailing 12-Months
Asset Growth
-3.37%
Trailing 12-Months
Company Description
Sinco Pharmaceuticals Holdings Ltd.
Sinco Pharmaceuticals Holdings Limited operates as an investment holding entity primarily specializing in the marketing, promotion, and distribution channel management of imported pharmaceutical products and medical devices throughout China. Its product portfolio includes Octapharma, a human albumin solution specifically for premature infants; Axetine, prescribed for a range of bacterial infections such as respiratory, urinary tract, soft tissue, gynecological, obstetrical, and gonorrheal infections, and for post-surgical infection prevention; and Medocef, used to treat bacterial infections affecting the lower respiratory tract (including pneumonia), urinary tract, bile duct, peritoneum, skin, soft tissue, pelvic area, and conditions like sepsis. The company also supplies Esafosfina, effective in managing hypophosphatemia and chronic ailments like alcohol intoxication, malnutrition, and respiratory failure due to low phosphate levels. Additionally, it offers Taurolite, a third-generation oral cholic acid drug for gallstone diseases, and Tamifil injection, indicated for metastatic prostate cancer, true precocious puberty, and endometriosis. Beyond these core services, Sinco Pharmaceuticals also conducts sales of medicinal products, operates warehousing facilities for pharmaceuticals, provides international trade services, and offers consultation in medical and biological technology. Established in 2011, the company's headquarters are situated in Chengdu, People's Republic of China, and it operates as a subsidiary of Risun Investments Limited.
Technical Analysis
Wanka Online, Inc.
―
Asiaray Media Group Ltd.
―
SEEC Media Group Limited
―
Netjoy Holdings Limited
―
Rego Interactive Co., Ltd.
―